Moderna to Cut mRNA Drug Substance Production at Lonza Facility Moderna to Cut mRNA Drug Substance Production at Lonza Facility

Moderna has said it will cut production of mRNA drug substance for its COVID-19 vaccine to align manufacturing of the shots with lower post-pandemic demand.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Infectious Diseases News Source Type: news